Impact of tacrolimus and mycophenolate mofetil regimen vs. a conventional therapy with steroids on cardiovascular risk in liver transplant patients

Clinical Transplantation

Volumn 29, Issue 8, 2015, Pages 667-677

  Cuervas Mons, Valentín ^a   Herrero, J Ignacio ^b,c   Gomez, Miguel A ^d   González Pinto, Ignacio ^e   Serrano, Trinidad ^f   de la Mata, Manuel ^c,g   Fabregat, Joan ^h   Gastaca, Mikel ⁱ   Bilbao, Itxarone ^c,j   Varo, Evaristo ^k   Sánchez Antolín, Gloria ^l   Rodrigo, Juan ^m   Espinosa, María Dolores ⁿ  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^e HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^f HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^g HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^h HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

ⁱ HOSPITAL DE CRUCES   (Spain)

^j HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^k University Hospital of Santiago de Compostela   (Spain)

^l HOSPITAL UNIVERSITARIO RÍO HORTEGA   (Spain)

^m HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

ⁿ Hepatology and Liver Transplantation Unit   (Spain)

more..

Author keywords

Cardiovascular risk factors; Immunosuppression; Liver transplantation; Mycophenolate mofetil; Steroids; Tacrolimus

Indexed keywords

CREATININE; METHYLPREDNISOLONE; MYCOPHENOLATE MOFETIL; TACROLIMUS; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; STEROID;

ADULT; AGED; ARTICLE; CARDIOMETABOLIC RISK; CAUSE OF DEATH; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; GRAFT RECIPIENT; GRAFT SURVIVAL; HEART DISEASE; HEMATOLOGIC DISEASE; HERNIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY FUNCTION; LABORATORY TEST; LIVER GRAFT; LIVER GRAFT REJECTION; MAJOR CLINICAL STUDY; MALE; OBESITY; OPPORTUNISTIC INFECTION; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE INFECTION; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; ADOLESCENT; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; CARDIOVASCULAR DISEASES; COMPARATIVE STUDY; COMPLICATION; FOLLOW UP; GRAFT REJECTION; LIVER DISEASES; LIVER TRANSPLANTATION; MIDDLE AGED; POSTOPERATIVE COMPLICATION; PROGNOSIS; PROSPECTIVE STUDY; RISK FACTOR; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CARDIOVASCULAR DISEASES; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER DISEASES; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; STEROIDS; TACROLIMUS; YOUNG ADULT;

EID: 84937512786     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/ctr.12557     Document Type: Article

References (41)

1. McCaughan GW, O'Brien E, Sheil AG. A follow up of 53 adult patients alive beyond 2years following liver transplantation. J Gastroenterol Hepatol 1993: 8: 569.
2. Stegall MD, Everson G, Schroter G etal. Metabolic complications after liver transplantation. Diabetes, hypercholesterolemia, hypertension, and obesity. Transplantation 1995: 60: 1057.
3. Guckelberger O, Bechstein WO, Neuhaus R etal. Cardiovascular risk factors in long-term follow-up after orthotopic liver transplantation. Clin Transplant 1997: 11: 60.
4. Sheiner PA, Magliocca JF, Bodian CA etal. Long-term medical complications in patients surviving > or = 5years after liver transplant. Transplantation 2000: 69: 781.
5. Fernandez-Miranda C, Sanz M, dela Calle A etal. Cardiovascular risk factors in 116 patients 5years or more after liver transplantation. Transpl Int 2002: 15: 556.
6. Johnston SD, Morris JK, Cramb R etal. Cardiovascular morbidity and mortality after orthotopic liver transplantation. Transplantation 2002: 73: 901.
7. Neal DA, Tom BD, Luan J etal. Is there disparity between risk and incidence of cardiovascular disease after liver transplant? Transplantation 2004: 77: 93.
8. Guckelberger O, Byram A, Klupp J etal. Coronary event rates in liver transplant recipients reflect the increased prevalence of cardiovascular risk-factors. Transpl Int 2005: 18: 967.
9. Mazuelos F, Abril J, Zaragoza C etal. Cardiovascular morbidity and obesity in adult liver transplant recipients. Transplant Proc 2003: 35: 1909.
10. Ciccarelli O, Kaczmarek B, Roggen F etal. Long-term medical complications and quality of life in adult recipients surviving 10years or more after liver transplantation. Acta Gastroenterol Belg 2005: 68: 323.
11. Hepático REdT. Memoria de resultados de 1984-2009. Sociedad Española de Trasplante Hepático. Available from: http://wwwsethepaticoorg/pdf/2009/MEMORIA_RETH_2009pdf.
12. Pruthi J, Medkiff KA, Esrason KT etal. Analysis of causes of death in liver transplant recipients who survived more than 3years. Liver Transpl 2001: 7: 811.
13. Canzanello VJ, Schwartz L, Taler SJ etal. Evolution of cardiovascular risk after liver transplantation: a comparison of cyclosporine A and tacrolimus (FK506). Liver Transpl Surg 1997: 3: 1.
14. Rabkin JM, Corless CL, Rosen HR etal. Immunosuppression impact on long-term cardiovascular complications after liver transplantation. Am J Surg 2002: 183: 595.
15. Meier-Kriesche HU, Li S, Gruessner RW etal. Immunosuppression: evolution in practice and trends, 1994-2004. Am J Transplant 2006: 6: 1111.
16. Bahirwani R, Reddy KR. Outcomes after liver transplantation: chronic kidney disease. Liver Transpl 2009: 15(Suppl 2): S70.
17. Stegall MD, Everson GT, Schroter G etal. Prednisone withdrawal late after adult liver transplantation reduces diabetes, hypertension, and hypercholesterolemia without causing graft loss. Hepatology 1997: 25: 173.
18. Stegall MD, Wachs ME, Everson G etal. Prednisone withdrawal 14days after liver transplantation with mycophenolate: a prospective trial of cyclosporine and tacrolimus. Transplantation 1997: 64: 1755.
19. Beckebaum S, Cicinnati VR, Klein CG etal. Impact of combined mycophenolate mofetil and low-dose calcineurin inhibitor therapy on renal function, cardiovascular risk factors, and graft function in liver transplant patients: preliminary results of an open prospective study. Transplant Proc 2004: 36: 2671.
20. Llado L, Fabregat J, Castellote J etal. Impact of immunosuppression without steroids on rejection and hepatitis C virus evolution after liver transplantation: results of a prospective randomized study. Liver Transpl 2008: 14: 1752.
21. Otero A, Varo E, de Urbina JO etal. A prospective randomized open study in liver transplant recipients: daclizumab, mycophenolate mofetil, and tacrolimus versus tacrolimus and steroids. Liver Transpl 2009: 15: 1542.
22. Marrugat J, D'Agostino R, Sullivan L etal. An adaptation of the Framingham coronary heart disease risk function to European Mediterranean areas. J Epidemiol Community Health 2003: 57: 634.
23. Ramos R, Solanas P, Cordon F etal. Comparison of population coronary heart disease risk estimated by the Framingham original and REGICOR calibrated functions. Med Clin 2003: 121: 521.
24. Chobanian AV, Bakris GL, Black HR etal. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003: 289: 2560.
25. Expert Committee on the D, Classification of Diabetes M. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003: 26(Suppl 1): S5.
26. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976: 16: 31.
27. O'Grady JG, Burroughs A, Hardy P etal. Tacrolimus versus microemulsified ciclosporin in liver transplantation: the TMC randomised controlled trial. Lancet 2002: 360: 1119.
28. Lucey MR, Abdelmalek MF, Gagliardi R etal. A comparison of tacrolimus and cyclosporine in liver transplantation: effects on renal function and cardiovascular risk status. Am J Transplant 2005: 5: 1111.
29. Kramer BK, Zulke C, Kammerl MC etal. Cardiovascular risk factors and estimated risk for CAD in a randomized trial comparing calcineurin inhibitors in renal transplantation. Am J Transplant 2003: 3: 982.
30. Wilson PW, D'Agostino RB, Levy D etal. Prediction of coronary heart disease using risk factor categories. Circulation 1998: 97: 1837.
31. Conroy RM, Pyorala K, Fitzgerald AP etal. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003: 24: 987.
32. Marrugat J, Solanas P, D'Agostino R etal. Coronary risk estimation in Spain using a calibrated Framingham function. Rev Esp Cardiol 2003: 56: 253.
33. Baena Diez JM, Salas Gaetgens LH, Altes Vaques E etal. REGICOR better than Framingham coronary risk function in Spain: good news for our patients. Med Clin 2004: 122: 597.
34. Buitrago F, Canon-Barroso L, Diaz-Herrera N etal. Comparison of the REGICOR and SCORE function charts for classifying cardiovascular risk and for selecting patients for hypolipidemic or antihypertensive treatment. Rev Esp Cardiol 2007: 60: 139.
35. Comin E, Solanas P, Cabezas C etal. Estimating cardiovascular risk in Spain using different algorithms. Rev Esp Cardiol 2007: 60: 693.
36. Marrugat J, Subirana I, Comin E etal. Validity of an adaptation of the Framingham cardiovascular risk function: the VERIFICA Study. J Epidemiol Community Health 2007: 61: 40.
37. London GM. Cardiovascular disease in chronic renal failure: pathophysiologic aspects. Semin Dial 2003: 16: 85.
38. Alipour N, Wong ND, Malik S. Diagnosis of coronary artery disease in persons with diabetes mellitus. Curr Diab Rep 2012: 12: 286.
39. Iwamoto T, Kagawa Y, Naito Y etal. Steroid-induced diabetes mellitus and related risk factors in patients with neurologic diseases. Pharmacotherapy 2004: 24: 508.
40. Yuen KC, McDaniel PA, Riddle MC. Twenty-four-hour profiles of plasma glucose, insulin, C-peptide and free fatty acid in subjects with varying degrees of glucose tolerance following short-term, medium-dose prednisone (20mg/day) treatment: evidence for differing effects on insulin secretion and action. Clin Endocrinol 2012: 77: 224.
41. Ramirez CB, Doria C, Frank AM etal. Completely steroid-free immunosuppression in liver transplantation: a randomized study. Clin Transplant 2013: 27: 463.